Advertisement
Singapore markets closed
  • Straits Times Index

    3,233.58
    -18.13 (-0.56%)
     
  • S&P 500

    5,248.49
    +44.91 (+0.86%)
     
  • Dow

    39,760.08
    +477.75 (+1.22%)
     
  • Nasdaq

    16,399.52
    +83.82 (+0.51%)
     
  • Bitcoin USD

    70,568.34
    +1,015.97 (+1.46%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,955.08
    +23.10 (+0.29%)
     
  • Gold

    2,216.60
    +3.90 (+0.18%)
     
  • Crude Oil

    81.74
    +0.39 (+0.48%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Nikkei

    40,168.07
    -594.66 (-1.46%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • FTSE Bursa Malaysia

    1,530.60
    -7.82 (-0.51%)
     
  • Jakarta Composite Index

    7,264.80
    -45.29 (-0.62%)
     
  • PSE Index

    6,903.53
    +5.36 (+0.08%)
     

Moderna (MRNA) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Moderna (MRNA) closed at $340.88, marking a -1.41% move from the previous day. This change lagged the S&P 500's daily loss of 0.51%.

Heading into today, shares of the biotechnology company had lost 10.01% over the past month, lagging the Medical sector's loss of 1.43% and the S&P 500's gain of 3.08% in that time.

MRNA will be looking to display strength as it nears its next earnings release, which is expected to be November 4, 2021. On that day, MRNA is projected to report earnings of $9.01 per share, which would represent year-over-year growth of 1627.12%. Meanwhile, our latest consensus estimate is calling for revenue of $6.09 billion, up 3757.76% from the prior-year quarter.

Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $29.46 per share and revenue of $20.14 billion. These totals would mark changes of +1603.06% and +2407.09%, respectively, from last year.

ADVERTISEMENT

It is also important to note the recent changes to analyst estimates for MRNA. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 1.14% higher within the past month. MRNA is currently a Zacks Rank #3 (Hold).

Valuation is also important, so investors should note that MRNA has a Forward P/E ratio of 11.74 right now. This valuation marks a discount compared to its industry's average Forward P/E of 27.48.

It is also worth noting that MRNA currently has a PEG ratio of 0.4. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. MRNA's industry had an average PEG ratio of 1.58 as of yesterday's close.

The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 170, putting it in the bottom 34% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Moderna, Inc. (MRNA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.